Forvisirvat

Last updated

Forvisirvat
Forvisirvat.svg
Clinical data
Other namesSP624
Routes of
administration 		Oral [1]
Drug class Sirtuin-6 (SIRT6) activator [1]
Identifiers
  • (2S,5'R)-7-chloro-3',4-dimethoxy-5'-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C19H17ClN2O6
Molar mass 404.80 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(C=C(C(=C3O2)Cl)C4=NN=C(O4)C)OC)OC
  • InChI=1S/C19H17ClN2O6/c1-8-5-10(23)6-13(26-4)19(8)17(24)14-12(25-3)7-11(15(20)16(14)28-19)18-22-21-9(2)27-18/h6-8H,5H2,1-4H3/t8-,19+/m1/s1
  • Key:MIHSWFYCAJWPIS-YLVJLNSGSA-N

Forvisirvat (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name SP-624) is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia. [1] [2] [3] [4] [5] It is taken by mouth. [1] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia. [1] [2] [4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures. [1] [2] [5]

See also

References

  1. 1 2 3 4 5 6 "SP 624". AdisInsight. 29 August 2024. Retrieved 23 October 2024.
  2. 1 2 3 "Delving into the Latest Updates on SP-624 with Synapse". Synapse. 21 September 2024. Retrieved 23 October 2024.
  3. ↑ Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W (2025). "Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults". Clinical Pharmacology in Drug Development. 14 (1): 18–25. doi: 10.1002/cpdd.1488 . ISSN   2160-763X. PMC   11701958 . PMID   39587867.
  4. 1 2 Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharmaceutica Sinica. B. 14 (3): 1009–1029. doi:10.1016/j.apsb.2023.10.023. PMC   10935124 . PMID   38486982.
  5. 1 2 "Depression treatment shows 'robust efficacy' in women in phase 2 trial". Daily Medical News, Free CME and Clinical Guidance. 19 October 2022. Retrieved 23 October 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.